209542-49-4

Basic information

• Product Name: m-PEG3-acid
• Synonyms: m-PEG3-acid;3-(2-(2-methoxyethoxy)ethoxy)propanoic acid;3-[2-(2-Methoxyethoxy)ethoxy]propionic acid;COOHCH2CH2-PEG2-OME;mPEG2-CH2COOH;mPEG3-COOH;mPEG2-CH2CH2COOH
• CAS NO: 209542-49-4
• Molecular Formula: C₈H₁₆O₅
• Molecular Weight: 192.21
• Product Categories: PEG-COOH
• Mol File: 209542-49-4.mol

Chemical Properties

• Boiling Point: 301.7±27.0 °C(Predicted)
• Appearance: /
• Density: 1.102±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Soluble in Water, DMSO, DCM, DMF
• PKA: 4.28±0.10(Predicted)
• CAS DataBase Reference: m-PEG3-acid(CAS DataBase Reference)
• NIST Chemistry Reference: m-PEG3-acid(209542-49-4)
• EPA Substance Registry System: m-PEG3-acid(209542-49-4)

Safety Data

• Hazardous Substances Data: 209542-49-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
m-PEG3-acid is used as a conjugation agent for improving the solubility and stability of therapeutic molecules. The ability of the terminal carboxylic acid to form stable amide bonds with primary amine groups allows for the attachment of drugs or targeting ligands to create more effective and bioavailable pharmaceutical products.
Used in Drug Delivery Systems:
In the field of drug delivery, m-PEG3-acid serves as a key component in the design of polymeric drug carriers. The hydrophilic PEG spacer can enhance the solubility and circulation time of drug-loaded nanoparticles or micelles, while the reactive carboxylic acid group enables the covalent attachment of drug molecules or targeting agents for precise delivery to specific cells or tissues.
Used in Bioconjugation and Chemical Synthesis:
m-PEG3-acid is utilized as a building block in the synthesis of bioconjugates and other complex molecules. The reactive carboxylic acid group facilitates the formation of amide bonds with primary amines, allowing for the creation of diverse molecular constructs with tailored properties and functions.
Used in Diagnostics and Imaging:
m-PEG3-acid can be employed in the development of contrast agents and imaging probes. By conjugating imaging labels or diagnostic molecules to the PEG linker via the carboxylic acid group, m-PEG3-acid can enhance the solubility and biocompatibility of these agents, potentially improving their performance in medical imaging and diagnostics.
Used in Cosmetics and Personal Care:
In the cosmetics and personal care industry, m-PEG3-acid is used as an ingredient to improve the solubility and stability of active ingredients. The hydrophilic PEG spacer can help to create formulations that are more compatible with skin and hair, potentially enhancing the efficacy and safety of cosmetic products.

Upstream product

• 111-77-3 2-(2-methoxyethoxy)ethyl alcohol 
• 1663-39-4 tert-Butyl acrylate 
• 1778219-81-0 tert-butyl 3-[2-(2-methoxyethoxy)ethoxy]propanoate 

Downstream Products

• 1333318-14-1 C₁₅H₂₄NO₇P 

Relevant articles and documents

ONIUM SALT, LIQUID COMPOSITION CONTAINING SAID ONIUM SALT AND CELLULOSE, AND CELLULOSE RECOVERY METHOD

The invention relates to an onium salt, a liquid composition containing the onium salt and cellulose, and a method for recovering cellulose. The invention makes it possible to provide an onium salt having an extremely high ability to dissolve cellulose at temperatures of 100° C. or lower. It also makes it possible to provide a liquid composition containing this onium salt and cellulose, as a composition suitable for the recovery of cellulose, and a method for recovering cellulose efficiently by using such a liquid composition containing the onium salt and cellulose.

Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery

A small library of novel 3-O-pegylated carboxylate prodrugs (4a-4b) and 3-O-pegylated carbamate prodrugs (9a-9b) of naltrexone were synthesized. The goal behind the design of these prodrugs was to investigate their potential for microneedle-enhanced transdermal delivery. All the synthesized 3-O-pegylated carboxylate prodrugs (4a-4b) and 3-O-pegylated carbamate prodrugs (9a-9b) of naltrexone were found to have adequate stability in a transdermal formulation and improved apparent solubility compared to naltrexone. Viscosity effects were postulated to be responsible for the observed non-linearity in the flux-concentration profile of these prodrugs.

Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof

Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition